Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CPGJ602 + inetetamab + chemotherapy in HER2-positive, RAS/BRAF wild-type metastatic colorectal cancer
CTR20212344Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CPGJ602 and inetetamab in colorectal cancer (CRC), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Phase Ib safety and tolerability and Phase II objective response rate by IRRC. Started Sep 2021; status: active.
02
Drugs
CPGJ602inetetamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20212344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212344.